Oncorus, Inc.

Oncorus, Inc. (ONCR) priced its initial public offering on Oct 2, 2020 at $15.00 per share, within its $14.00–$16.00 range, raising $87M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $327.7M. Jefferies was lead-left underwriter, joined by Evercore ISI and Piper Sandler. Cooley advised the company and WilmerHale advised the underwriters.

Oncorus, Inc. is a clinical-stage biopharmaceutical company developing viral immunotherapies for cancer using two proprietary platforms. Its lead candidate, ONCR-177, is an intratumorally administered oncolytic herpes simplex virus engineered to carry multiple immunostimulatory transgenes.

Status

IPO

Ticker

ONCR

Exchange

Nasdaq Global Market

Priced

Oct 2, 2020

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$87M

Market cap at IPO price

$327.7M

First filed

Sep 11, 2020

Underwriters

Jefferies, Evercore ISI and Piper Sandler

Company counsel

Cooley

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.